CAPTRUST Financial Advisors
VERV

CAPTRUST Financial Advisors’s Verve Therapeutics VERV Stock Holding History

CAPTRUST Financial Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4
Closed – – 3994
2022
Q2 		$0 Buy
+4
New +$62 ﹤0.01% 5158
2021
Q4 		– Sell
-64
Closed -$3K – 4922
2021
Q3 		$3K Buy
+64
New +$3.77K ﹤0.01% 4155

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

CAPTRUST Financial Advisors's VERV Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Verve Therapeutics (VERV) in Q3 2022, closing a stake of 4 shares.

CAPTRUST Financial Advisors first reported a position in VERV in Q3 2021 and held it in 2 quarters. The position peaked at $3K in Q3 2021. 125 funds tracked by Wall St. Rank hold VERV as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Verve Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 4 Verve Therapeutics shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in Verve Therapeutics in Q3 2021 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Verve Therapeutics position peaked at $3K in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.